Consistent with previous studies with EGFR1/HER2(ERBB2)-targeted tyrosine kinase inhibitors (TKIs) [34, 40], we found that Lapatinib can cause FOXO3-dephosphorylation (T32) and the downregulation of its target FOXM1 in Lapatinib-sensitive NPC cells. The gene discussed is ERBB2; the disease is nasopharyngeal carcinoma.